

# Anil Shanker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656595/publications.pdf>

Version: 2024-02-01

83  
papers

1,782  
citations

257450

24  
h-index

289244

40  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2694  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial Fus1/Tusc2 and cellular Ca <sup>2+</sup> homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. <i>Cancer Gene Therapy</i> , 2022, 29, 1307-1320.	4.6	4
2	Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. <i>Frontiers in Immunology</i> , 2021, 12, 607044.	4.8	16
3	Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. <i>Cancer Research</i> , 2021, 81, 3374-3386.	0.9	11
4	The rapid endocytic uptake of fetuin <sup>A</sup> by adherent tumor cells is mediated by Toll <sup>A</sup> -like receptor 4 (TLR4). <i>FEBS Open Bio</i> , 2020, 10, 2722-2732.	2.3	1
5	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non <sup>A</sup> -Small-Cell Lung <sup>A</sup> Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020, 21, 520-526.	2.6	8
6	Critical Neurotransmitters in the Neuroimmune Network. <i>Frontiers in Immunology</i> , 2020, 11, 1869.	4.8	86
7	Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. <i>Frontiers in Immunology</i> , 2020, 11, 1958.	4.8	15
8	Abstract C135: Notch as an immunologic basis of cancer disparity. , 2020, , .		0
9	CD8 <sup>+</sup> T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1906.	4.8	84
10	Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T <sup>A</sup> cell immunity. , 2019, 7, 95.		31
11	Editorial: Lymphocyte Functional Crosstalk and Regulation. <i>Frontiers in Immunology</i> , 2019, 10, 2916.	4.8	6
12	Update <sup>A</sup> on the current revolution in cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 15-20.	2.0	12
13	Notch as an Immunologic Basis of Cancer Disparities. <i>Cancer Health Disparities</i> , 2019, 3, e1-e10.	0.5	0
14	Prospects of combining adoptive cell immunotherapy with bortezomib. <i>Immunotherapy</i> , 2017, 9, 305-308.	2.0	3
15	Innate-Adaptive Immune Crosstalk 2016. <i>Journal of Immunology Research</i> , 2017, 2017, 1-2.	2.2	8
16	Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8 <sup>+</sup> T cell antitumor function. <i>Oncotarget</i> , 2017, 8, 8604-8621.	1.8	16
17	Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. <i>Aging</i> , 2017, 9, 627-649.	3.1	20
18	Abstract 5665: Physical crosstalk between CD8 <sup>+</sup> T and natural killer cells elicits antitumor effector response. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract 647: Bortezomib enhances CD8+T Lymphocyte antitumor effector function: Potential mechanism(s) via notch regulation. , 2017, , .		0
20	Computational properties of mitochondria in T cell activation and fate. Open Biology, 2016, 6, 160192.	3.6	5
21	Validation of research trajectory 1 of an Exposome framework: Exposure to benzo(a)pyrene confers enhanced susceptibility to bacterial infection. Environmental Research, 2016, 146, 173-184.	7.5	15
22	Tributyltin exposure alters cytokine levels in mouse serum. Journal of Immunotoxicology, 2016, 13, 870-878.	1.7	5
23	Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine, 2016, 84, 74-87.	3.2	22
24	Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity. Oncolmmunology, 2016, 5, e1122864.	4.6	5
25	Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunology Letters, 2016, 169, 61-72.	2.5	42
26	Abstract 4161: Bortezomib enhances expression of effector molecules in antitumor CD8+ T lymphocytes by modulating Notch-NF-kB-miR-155 crosstalk. , 2016, , .		1
27	Abstract 934: Tributyltin-induced dysregulation of inflammatory cytokine levels in human and mouse immune cells. , 2016, , .		0
28	From immunogenetic polymorphism to functional antitumor lymphocyte mitochondrial dynamics. , 2015, 3, O13.		0
29	Modulatory effects of bortezomib on host immune cell functions. Immunotherapy, 2015, 7, 1011-1022.	2.0	52
30	Upregulation of neuroreceptors on CD4+ and CD8+ T cells promotes their anti-tumor function. , 2015, 3, P322.		0
31	Innate-Adaptive Immune Crosstalk. Journal of Immunology Research, 2015, 2015, 1-2.	2.2	4
32	Promise of Immunotherapy in Lung Cancer. Progress in Tumor Research, 2015, 42, 95-109.	0.1	2
33	Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters, 2015, 166, 117-133.	2.5	41
34	Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Research, 2015, 75, 5260-5272.	0.9	26
35	Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Research, 2015, 75, 4728-4741.	0.9	49
36	Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget, 2015, 6, 20754-20772.	1.8	34

#	ARTICLE	IF	CITATIONS
37	Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor- $\kappa$ B crosstalk. <i>Oncotarget</i> , 2015, 6, 32439-32455.	1.8	28
38	Abstract 2735: Tributyltin alters the production and secretion of inflammatory cytokines from human and mouse immune cells. , 2015, , .		0
39	Abstract 4059: Crosstalk between CD8+ T and NK cells: fine-tuning of antitumor immune response. , 2015, , .		0
40	Abstract B45: Mitochondrial Ca <sup>2+</sup> transport fine-tunes functional cross-talk between antitumor CD8+T lymphocytes and natural killer cells. , 2015, , .		0
41	Cancer therapy by resuscitating Notch immune surveillance. , 2014, 2, .		1
42	Fus1/Tusc2 Is a Novel Regulator of Mitochondrial Calcium Handling, Ca <sup>2+</sup> -Coupled Mitochondrial Processes, and Ca <sup>2+</sup> -Dependent NFAT and NF- $\kappa$ B Pathways in CD4 <sup>+</sup> T Cells. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1533-1547.	5.4	33
43	Bortezomib enhances anti-tumor T cell immunity by remodeling Notch system. , 2014, 2, .		0
44	Cross-talk between CD8+ T cells and natural killers: the role of mitochondrial Aa <sup>2+</sup> transport. , 2014, 2, .		0
45	Modulation of anti-tumor lymphocyte function by neurotransmitter glutamate. , 2014, 2, P38.		0
46	Abstract 3642: Cancer therapy by resuscitating Notch immune surveillance. , 2014, , .		0
47	Abstract 1177: Pharmacological stimulation of DLL1-Notch signaling as an effective cancer immunotherapy. , 2014, , .		1
48	Abstract 3191: Elevation of tumor-promoting cytokines in mice exposed to the environmental contaminant tributyltin. , 2014, , .		0
49	Cancer therapy by restoration of immune Notch. , 2013, 1, .		0
50	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 145.	4.4	82
51	Abstract 3983: Resuscitating immune surveillance in cancer.. , 2013, , .		0
52	Development of Proteasome Inhibitors as Therapeutic Drugs. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2012, 01, 5.	1.5	23
53	Lymphocyte Teamwork in Tumor Rejection. , 2012, , 411-413.		0
54	Abstract A9: Pharmacological stimulation of DLL1-Notch signaling as an antitumor immunotherapy. <i>Clinical Cancer Research</i> , 2012, 18, A9-A9.	7.0	0

#	ARTICLE	IF	CITATIONS
55	Abstract B93: Resuscitating cancer immunosurveillance by combining Notch 1 and death receptor-activating therapy. , 2012, , .		0
56	Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunology, Immunotherapy, 2011, 60, 1061-1074.	4.2	45
57	NK cells: immune cross-talk and therapeutic implications. Immunotherapy, 2011, 3, 1143-1166.	2.0	88
58	Resuscitating Cancer Immun-surveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth. Cancer Research, 2011, 71, 6122-6131.	0.9	64
59	Neuroendocrine Crosstalk of Immunity. Journal of Blood & Lymph, 2011, 01, .	0.0	2
60	The Immune Rejection: Lessons from Experimental Models. , 2011, , 17-25.		0
61	Abstract B107: Combination therapy of kidney cancer using bortezomib and natural killer (NK) cell transfer. , 2011, , .		0
62	Abstract B108: Combining Notch immunostimulation and bortezomib with adoptive immunotherapy in breast cancer. , 2011, , .		0
63	Adaptive control of innate immunity. Immunology Letters, 2010, 131, 107-112.	2.5	23
64	Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T cell receptor diversity. Immunology, 2010, 129, 41-54.	4.4	36
65	Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex. Molecular Cancer Research, 2010, 8, 729-738.	3.4	63
66	Abstract 4251: Murine hepatocellular carcinoma stem cells express pluri-potency-associated transcription factors and are sensitive to immune-mediated apoptosis. , 2010, , .		0
67	Abstract 1931: Impact of bortezomib-induced proteasome inhibition in vivo on antitumor T cell responses. , 2010, , .		0
68	Antigen Presented by Tumors <i>In vivo</i> Determines the Nature of CD8+ T-Cell Cytotoxicity. Cancer Research, 2009, 69, 6615-6623.	0.9	38
69	Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition. Journal of Immunology, 2008, 180, 163-170.	0.8	138
70	Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody. Journal of the National Cancer Institute, 2008, 100, 649-662.	6.3	83
71	CD8 T Cell Help for Innate Antitumor Immunity. Journal of Immunology, 2007, 179, 6651-6662.	0.8	94
72	Sensitizing Tumor Cells to Immune-Mediated Cytotoxicity. Advances in Experimental Medicine and Biology, 2007, 601, 163-171.	1.6	10

#	ARTICLE	IF	CITATIONS
73	TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. <i>Immunology and Cell Biology</i> , 2006, 84, 87-98.	2.3	83
74	NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function. <i>Journal of Immunology</i> , 2006, 177, 2575-2583.	0.8	19
75	Tumor Therapy With Proteasome Inhibitor Bortezomib (Velcade, PS-341) Plus Death Receptor (DR5) Agonist Antibody MD5.1. <i>Journal of Immunotherapy</i> , 2005, 28, 641.	2.4	0
76	Thymocyte-Intrinsic Genetic Factors Influence CD8 T Cell Lineage Commitment and Affect Selection of a Tumor-Reactive TCR. <i>Journal of Immunology</i> , 2004, 172, 5069-5077.	0.8	19
77	Is thymus redundant after adulthood?. <i>Immunology Letters</i> , 2004, 91, 79-86.	2.5	46
78	Antitumor Effect of Some 3d-Metal Complexes of N-Isonicotinoyl-N'-o-Hydroxythiobenzhydrazide. <i>Bioinorganic Chemistry and Applications</i> , 2003, 1, 255-270.	4.1	5
79	Corrigendum to "Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin" [FEMS Immunol. Med. Microbiol. 27 (2000) 247-255]. <i>FEMS Immunology and Medical Microbiology</i> , 2001, 31, 235.	2.7	0
80	Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin $\alpha$ -1. <i>International Journal of Immunopharmacology</i> , 2000, 22, 309-321.	1.1	24
81	Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. <i>FEMS Immunology and Medical Microbiology</i> , 2000, 27, 247-255.	2.7	22
82	Ascitic Growth of a Spontaneous Transplantable T Cell Lymphoma Induces Thymic Involution. <i>Tumor Biology</i> , 2000, 21, 315-327.	1.8	40
83	Ascitic Growth of a Spontaneous Transplantable T Cell Lymphoma Induces Thymic Involution. <i>Tumor Biology</i> , 2000, 21, 288-298.	1.8	42